Presently, the company continues research and development activity on anti-aging medicine, immunotherapeutic approach for cancer treatment and regenerative medicine. Particularly, these R&D projects are performed:
- Xenogenic anticancer vaccine preclinical investigation in murine models.
- Cellular mitochondrial transfer technology, preclinical investigation in vitro and in murine models.
- Project “M”, mice lifespan prolongation with the use of cellular, subcellular and biopharmaceutical approach.
During many years of research activity, the company has developed a number of technologies to overcome disbalances of biological systems, preparing drugs from the own tissues and cells of the patient. Personalized approach to treat a disease is the main target in our technologies. The current activities of the company are presented as follows:
|Lifespan prolongation with the use of cellular, subcellular and biopharmaceutical approaches.||Age-related diseases.||In vitro and in vivo experimental studies.|
|Antitumor adoptive leukocyte immunotherapy.||Melanoma; renal cancer; colorectal cancer; gastric cancer; brain cancer; prostate cancer; lung cancer; breast cancer; thyroid carcinoma; ovarian carcinoma; pancreas cancer.||In vitro and in vivo experimental studies; clinical investigations.|
|Antibacterial adoptive leukocyte immunotherapy.||Chronic cystitis; chronic maxillary sinusitis, chronic otitus.||Clinical investigations.|
|Reparative adoptive leukocyte immunotherapy.||Osteoarthritis; arthritis; osteomyelitis; atrophic scar (post acne); alopecia; trophic ulcer; and eczema.||Clinical investigations.|
|Antitumor cellular vaccination.||Melanoma; renal cancer; colorectal cancer; gastric cancer; brain cancer; prostate cancer; lung cancer; breast cancer; thyroid carcinoma; ovarian carcinoma; pancreas cancer.||In vitro and in vivo experimental studies; clinical investigations.|
|T-cell immunotherapy (T-cell vaccination).||Multiple sclerosis; rheumatoid arthritis; psoriasis; spondylitis deformans; autoimmune vasculitis.||Clinical investigations.|
Innovita Research holds these patents for its technologies:
- Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated, antigens.
Seledtsov V.I., Darinskas A., Seledtsova G.V. Patent WO 2016046651 A1, 2016..
The company provides a number of products for scientific research purposes:
- cord blood plasma;
- mesenchymal stem cells;
- polyantigenic anticancer vaccine;
- cell lines;
- cell-based products.
The company uses Good Laboratory Practice (GLP) certified system for research activity and Good Manufacturing Practice (GMP) certified entities for small-scale production of cellular products for preclinical investigations.
Innovita Research also offers high quality pre-clinical trials performance service of any kind of customer substance, device or technology.